Health care professionals can register today for the Pulmonary Hypertension Association’s (PHA’s) 2019 PH Professional Network (PHPN) Symposium Sept. 5-7 in Washington, D.C., and take advantage of their proximity to Capitol Hill during Advocacy Day on Sept. 5. Nurses, respiratory therapists and physicians can advocate for their patients and their practice in facilitated, small
The Pulmonary Hypertension Association’s (PHA’s) PH Care Centers (PHCC) Program recently accredited five new centers in support of its commitment to promoting quality care practices through PH center accreditation. Interest in PHA’s continuous quality improvement initiative remains high as PH programs seek accreditation as Centers of Comprehensive Care (CCC) and Regional Clinical Programs (RCP).
The Pulmonary Hypertension Association (PHA) just launched its new Clinical Trial Finder that allows individuals to search for research in pulmonary hypertension (PH), so it seems fitting to highlight a paper published in the most recent edition of Advances in Pulmonary Hypertension, “Basic Science and Clinical Trials: Accelerating the Future.” Authors Stephen J. Halliday,
Although the World Symposium on Pulmonary Hypertension (WSPH) has led pulmonary hypertension (PH) to be considered in five classifications, or groups, pediatric PH is more nuanced and there is increasing recognition of unique genotypic and phenotypic subsets of the disease. This necessitates individualized and precision approaches to treatments for children with PH that will
The latest issue of Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension Association (PHA) — a free quarterly publication directed by an editorial board of renowned pulmonary hypertension (PH) experts — includes an article by Brian Graham, M.D., Peter Fernandes, M. Pharm., and Sue Gu, M.D., that explores the barriers and solutions to
The Pulmonary Hypertension Association (PHA) recently published three new courses on PHA Online University, a program of PHA’s multi-sponsored Medical Education Fund and the go-to web platform for health care professionals to acquire relevant and reliable information about pulmonary hypertension (PH). The courses are part of the “Pulmonary Hypertension: The Basics” curriculum series to educate
A new Data Analysis Service launched this week by the Pulmonary Hypertension Association (PHA) enables researchers and organizations not involved in PHA’s Pulmonary Hypertension Association Registry (PHAR) to use data from the multi-center patient registry. PHAR is part of an innovative and critical PHA initiative to improve care for persons with pulmonary hypertension (PH),
The diagnosis of pulmonary hypertension (PH) is overwhelming in patients’ and caregivers’ lives. It also can prove challenging to health care professionals new to the field. Before health care professionals were experts, they were studying and training underneath their mentors to learn quality patient care and implement best practices. The Pulmonary Hypertension Association’s (PHA) PH
Although treatment options for WHO Group 1 PH (pulmonary arterial hypertension, or PAH) have increased over the past few decades, symptom severity and quality of life still impose significant burden on patients. Palliative care – often confused with hospice care – is goal-oriented care for patients with chronic illnesses that help to balance life-saving
The Pulmonary Hypertension Association (PHA) recently learned that the Food and Drug Administration (FDA) has approved a generic version of tadalafil, the pulmonary arterial hypertension (PAH)-targeted therapy sold as Adcirca®. Availability of the generic therapy for patients remains to-be-determined. PHA also has been advised that generic versions of other PAH-targeted therapies may become available soon.